GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (STU:7F0) » Definitions » Debt-to-Asset

Fulgent Genetics (STU:7F0) Debt-to-Asset : 0.01 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulgent Genetics Debt-to-Asset?

Fulgent Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.7 Mil. Fulgent Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €6.4 Mil. Fulgent Genetics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €1,111.6 Mil. Fulgent Genetics's debt to asset for the quarter that ended in Sep. 2024 was 0.01.


Fulgent Genetics Debt-to-Asset Historical Data

The historical data trend for Fulgent Genetics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Debt-to-Asset Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.02 0.03 0.01

Fulgent Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 0.01 0.01

Competitive Comparison of Fulgent Genetics's Debt-to-Asset

For the Diagnostics & Research subindustry, Fulgent Genetics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Debt-to-Asset falls into.



Fulgent Genetics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Fulgent Genetics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.713 + 9.272) / 1132.796
=0.01

Fulgent Genetics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.706 + 6.447) / 1111.62
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (STU:7F0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Fulgent Genetics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics Business Description

Traded in Other Exchanges
Address
4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics Headlines

No Headlines